The Worldwide Immune Checkpoint Inhibitors Market is Projected to reach USD 75.9 Billion by 2027, at a CAGR of 16.1%

Immune Checkpoint Inhibitors Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Immune Checkpoint Inhibitors Market size is expected to reach $75.9 billion by 2027, rising at a market growth of 16.1% CAGR during the forecast period.

The Lung Cancer segment is leading the Global Immune Checkpoint Inhibitors Market by Application 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $28.2 billion by 2027. The rising prevalence of patients with lung cancer is a major reason behind the adoption of these drugs and treatments in order to cure lung cancer across the world. These medications prevent the cancer cells to attack non-harmful cells across the body. Moreover, Immune checkpoint inhibitors have revolutionized the treatment of non–small cell lung cancer (NSCLC) and are currently being tested in small cell lung cancer patients.

The PD-L1 Inhibitor segment has high growth rate of 16.6% during (2021 - 2027). PD-L1 inhibitors are a class of immune checkpoint inhibitors that are used as front-line treatments for a variety of cancers. The growth of this segment across the market is attributed to an increase in the utilization of durvalumab and avelumab, as well as a boom in PD-L1 inhibitor-related research and development activities.

The North America region is generating high revenue in the Global Immune Checkpoint Inhibitors Market by Region 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $42.2 billion by 2027. The Europe market is exhibiting a CAGR of 16.4% during (2021 - 2027). Additionally, The Asia Pacific market would showcase a CAGR of 16.9% during (2021 - 2027).

Full Report: https://www.kbvresearch.com/immune-checkpoint-inhibitors-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AstraZeneca PLC, Beigene Ltd., Shanghai Junshi Biosciences Co., Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Merck Group (Merck Sharp & Dohme Corp.), Sanofi S.A., Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.

Global Immune Checkpoint Inhibitors Market Segmentation

By Application

• Lung Cancer
• Bladder Cancer
• Melanoma
• Hodgkin lymphoma
• Others

By Type

• PD-1 Inhibitor
• PD-L1 Inhibitor
• CTLA-4 Inhibitor

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• AstraZeneca PLC
• Beigene Ltd.
• Shanghai Junshi Biosciences Co., Ltd.
• Bristol Myers Squibb Company
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Merck Group (Merck Sharp & Dohme Corp.)
• Sanofi S.A.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.

Related Reports:

North America Immune Checkpoint Inhibitors Market Size 2027

• March-2022
• 83 Pages

LAMEA Immune Checkpoint Inhibitors Market Size Report 2027

• March-2022
• 92 Pages

Europe Immune Checkpoint Inhibitors Market Size & Trends 2027

• March-2022
• 91 Pages

Asia Pacific Immune Checkpoint Inhibitors Market Size by 2027

• March-2022
• 93 Pages